Researcher Discovers Protein That Inhibits Cervical Cancer Growth
Gary Fournier, a managing director with JP Morgan, provides financial guidance and portfolio management to high-net-worth clients. Aside from his professional activities, Gary Fournier and his wife Debi have partnered with UCLA’s Jonsson Cancer Center Foundation to establish a fund for research that will lead to new treatments and deeper understanding of cervical cancer. The fund is called the Debi and Gary Fournier Cervical Cancer Research Fund.
Worldwide, over 500,000 women are diagnosed with cervical cancer each year. Though the causes of cervical cancer vary, most cases are caused by a sexually transmitted virus called human papillomavirus (HPV). The virus is detected in 90 percent of all cervical cancer tumors.
Scientists at UCLA’s Jonsson Comprehensive Cancer Center continue to make important discoveries related to cervical cancers. Dr. Eri Srivatsan, a UCLA researcher and member of the Jonsson Comprehensive Cancer Center, recently identified a protein that can potentially limit the growth of cervical cancer cells. The protein, cystatin E/M, has been shown to inhibit the cellular inflammation that results from HPV. Unmitigated, the inflammation fuels the growth of cancer cells.
In the five-year study, Dr. Eri Srivatsan discovered that cystatin E/M is a regulator of harmful inflammation. In coming years, he will continue to work with the protein to determine its effectiveness in inhibiting the growth of other types of tumors.